Lista de obras -

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years

artículo científico publicado en 2016

Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis

artículo científico publicado en 2016

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study

article

Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients

artículo científico publicado en 2012

Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma

artículo científico publicado en 2011

Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era.

artículo científico publicado en 2012

No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years

scientific article published on 20 April 2011

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

artículo científico publicado en 2005

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

artículo científico publicado en 2013

Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase

artículo científico publicado en 2009

Prognostication of the High-Risk WM Patient

artículo científico publicado en 2011

Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents

artículo científico publicado en 2007

Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents

artículo científico publicado en 2010

Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy

Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors

artículo científico publicado en 2004

Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)